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In Brief
Plasmodium infection rarely results in
sterilizing immunity, which may be
partially due to infection-induced
immuno-inhibitory circuits. Zander et al.
show that OX40 co-stimulatory signaling
improves immunity and limits parasite
growth. Crosstalk between OX40 co-
stimulatory and PD-1 co-inhibitory
pathways reveals a role for IFN-g in
constraining humoral immunity and
parasite clearance.
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The differentiation and protective capacity of
Plasmodium-specific T cells are regulated by both
positive and negative signals during malaria, but
the molecular and cellular details remain poorly
defined. Here we show that malaria patients and
Plasmodium-infected rodents exhibit atypical ex-
pression of the co-stimulatory receptor OX40 on
CD4 T cells and that therapeutic enhancement of
OX40 signaling enhances helper CD4 T cell activity,
humoral immunity, and parasite clearance in rodents.
However, these beneficial effects of OX40 signaling
are abrogated following coordinate blockade of
PD-1 co-inhibitory pathways, which are also upregu-
lated during malaria and associated with elevated
parasitemia. Co-administration of biologics blocking
PD-1 and promoting OX40 signaling induces exces-
sive interferon-gamma that directly limits helper
T cell-mediated support of humoral immunity and
decreases parasite control. Our results show that tar-
geting OX40 can enhance Plasmodium control and
that crosstalk between co-inhibitory and co-stimula-
tory pathways in pathogen-specific CD4 T cells can
impact pathogen clearance.
INTRODUCTION
Plasmodium infections and the disease malaria remain
global health emergencies (World Health Organization, 2013).
Although clinical immunity against malaria is documented
following repeated exposure to Plasmodium parasites, steril-
izing immunity against the parasite rarely, if ever, develops
(Tran et al., 2013). Many studies show that immune-mediated
resistance against blood-stage Plasmodium infection requires
the activity of T and B cells (Amante and Good, 1997, 2001;
Butler et al., 2012; Elliott et al., 2005; Kumar and Miller, 1990;
Langhorne, 1989; Pombo et al., 2002; Riley et al., 2006). How-
ever, the extent to which T cell-expressed immunoregulatory628 Cell Host & Microbe 17, 628–641, May 13, 2015 ª2015 Elsevier Ireceptors either promote or constrain the generation of potent
anti-Plasmodium T and B cell-meditated immunity remains
poorly defined.
Previous work showed that P. falciparum infection is asso-
ciated with the expression of inhibitory receptors that are
known to limit the activity of parasite-specific lymphocytes
(Illingworth et al., 2013). We and others have shown that the
receptors programmed cell death 1 (PD-1) and/or lympho-
cyte-activation gene 3 (LAG-3) are aberrantly expressed during
rodent malaria and that they contribute to dysfunctional para-
site-specific T cell responses and limit parasite clearance
(Butler et al., 2012; Horne-Debets et al., 2013). In contrast to
negative regulatory circuits, whether co-stimulatory pathways
additionally regulate an established T cell response during
prolonged or chronic Plasmodium infection is not known. More-
over, whether negative co-inhibitory circuits are functionally
counterbalanced by co-stimulatory networks to maintain
T cell immunity during blood-stage Plasmodium infection has
not been examined.
One co-stimulatory molecule that could play an important
role during Plasmodium infection is the OX40 receptor. OX40 is
a member of the tumor necrosis factor receptor (TNFR) super-
family and is reported to be transiently expressed on T cells
following cognate interactions between T cell receptors (TCRs)
and antigen-major histocompatibility (MHC) complexes on
antigen presenting cells (APCs) (Croft, 2010). OX40 signaling
promotes T cell proliferation and survival, influences CD4 T cell
differentiation into T helper type I (Th1), type 2 (Th2), and T follic-
ular helper (Tfh) cell subsets (Croft, 2010; Walker et al., 1999) and
is reported to reverse CD4 T cell hypo-responsiveness (Bansal-
Pakala et al., 2001). For these reasons, we hypothesized that
therapeutic ligation of OX40 during Plasmodium blood-stage
infection would enhance parasite-specific CD4 T cell activity,
limit the degree of CD4 T cell exhaustion, and promote parasite
clearance from the host.
Here, we report marked upregulation of OX40 on CD4 T cells
during human and rodent malaria, with atypical patterns of
sustained OX40 expression in rodents. Therapeutic enhance-
ment of OX40 signaling during established rodent malaria
promoted the accumulation of multiple functionally distinct
CD4 T cell subsets, enhanced T-dependent humoral immunity,
and limited parasite growth. Strikingly, co-administration ofnc.
biologics to block PD-1 and promote OX40 signaling obstructed
Tfh and germinal center (GC) reactions in an interferon-gamma
(IFN-g)-dependent manner, resulting in loss of antibody-medi-
ated parasite control. Collectively, our results demonstrate
that excess IFN-g can block the differentiation or survival of
Plasmodium-specific Tfh cells during blood-stage infection.
Moreover, our data reveal that crosstalk between T cell co-stim-
ulatory and co-inhibitory signaling pathways during malaria
modulates cellular and humoral immunity, which has broad
implications for immunotherapeutic strategies designed to
impact the function of CD4 T cells during persistent infection
or cancer.
RESULTS
Blood-Stage Plasmodium Infection Induces OX40
Expression on Human and Rodent CD4 T Cells
We first examined whether P. falciparum infection was associ-
ated with changes in OX40 and PD-1 expression in a longitudinal
cohort of children in Mali whose circulating CD4 T cells were
examined at the healthy baseline before febrile malaria and
7 days after anti-malarial treatment. The mean fluorescence
intensities (MFI) of OX40 and PD-1 were significantly elevated
on CD45RO+CD45RA CD4 T cells (Figure S1A) 7 days after
treatment (Figure 1A), and the upregulation of PD-1 expression
on CD4 T cells also positively correlated with parasite burden
in the blood during febrile malaria (Figure 1B). To determine
whether these patterns were paralleled during rodent malaria,
we examined their expression on parasite-specific splenic
CD4+ (CD11ahiCD49dhi) and CD8+ (CD11ahiCD8alo) T cells (But-
ler et al., 2012) at various times after P. yoelii infection. On day 7
post-infection (p.i.), OX40 was expressed by a large fraction
(>50%) of parasite-specific CD4 T cells, but not CD8 T cells (Fig-
ure 1C). Strikingly, OX40 expression was sustained on parasite-
specific CD4 T cells through day 28 p.i. (Figure 1D). OX40 was
also expressed by >70% of CXCR5+PD-1hi T follicular helper
(Tfh) cells (Figure S1B) and both resting (CD11aloCD44lo) and
activated (CD11ahiCD44hi) Foxp3+ T regulatory cells (Tregs) on
day 14 p.i. (Figure S1C). Notably, Tregs comprised 15% of all
OX40+ CD4 T cells following P. yoelii infection (Figure S1D),
supporting that the majority (85%) of OX40+ cells represent
other functionally distinct, parasite-specific effector andmemory
CD4 T cell populations. We also assayed several other cell types
(not shown) and found that only a subset of NK cells expressed
OX40 after blood-stage P. yoelii infection (Figure S1E). Consis-
tent with our previous report (Butler et al., 2012), we found that
higher parasite burden was associated with sustained, coordi-
nate expression of co-inhibitory receptors PD-1 and LAG-3 (Fig-
ures 1E and 1F). Moreover, OX40 was coordinately expressed
with PD-1 and LAG-3, with highest PD-1, LAG-3, and OX40
expression on CD4 T cells in mice with highest parasite burdens
(Figures 1E, 1F, and S1F). These data show that humanmalaria is
associated with the upregulation of both co-inhibitory (PD-1) and
co-stimulatory (OX40) receptors on CD4 T cells. Moreover, coor-
dinate expression of PD-1, LAG-3, and OX40 on rodent CD4
T cells is consistent with the notion that co-inhibitory receptor
signalingmay bemodified or counterbalanced by co-stimulatory
signaling pathways in CD4 T cells responding to Plasmodium
infection.Cell HThe OX40-OX40L Pathway Regulates
Plasmodium-Specific CD4 T Cell Responses
and Control of Blood-Stage P. yoelii Infection
To directly test whether the OX40 co-stimulatory pathway is bio-
logically relevant during an established Plasmodium infection,
we manipulated this pathway in vivo by administering one of
two biologics to P. yoelli-infected mice (Figure 2A). We used
either an antagonistic (blocking) monoclonal antibody (mAb)
directed against OX40L (Akiba et al., 1999) or an agonistic (stim-
ulating) mAb that triggers OX40 signaling pathways in cells ex-
pressing OX40 (Gramaglia et al., 2000). Daily administration of
the a-OX40L blockingmAb fromday 7 to 10 p.i. resulted in signif-
icantly elevated parasite burdens, compared to mice receiving
control rIgG mAb (Figure 2B). Conversely, P. yoelii-infected
mice injected with agonistic a-OX40 mAb on days 7 and 10 p.i.
exhibited significantly reduced peak parasitemia compared to
mice administered control rIgG (Figure 2C).
Given that OX40 expression was primarily restricted to CD4
T cells and NK cells during rodent malaria, we examined specific
attributes of these cells following a-OX40 treatment. Consistent
with the notion that co-stimulatory pathways counterbalance
co-inhibitory signaling, a-OX40 agonistic mAb resulted in a
25% increase in the proportion of parasite-specific CD4 T cells
expressing Ki67, a marker of recent proliferation (Figures S2A
and S2B). However, a-OX40 treatment did not increase splenic
NK cell numbers, degranulation, or cytokine secreting capacity
(Figures S2C–S2E). In contrast, we found that OX40 agonistic
mAb treatment resulted in 3- to 4-fold expansions in the
frequency and number of parasite-specific CD4 T cells by
day 14 p.i., an effect that was sustained through day 28 p.i.
(Figures 2D–2F). Collectively, these data show that
sustained OX40 signaling regulates the magnitude of the CD4
T cell response and parasite control following blood-stage
Plasmodium infection.
The OX40-OX40L Pathway Modulates the
Differentiation and Accumulation of T Helper Type I
Plasmodium-Specific CD4 T Cells
To formally test whether CD4 T cells are necessary for the in vivo
protective effects of a-OX40 during experimental malaria, we
repeated our studies in CD4 T cell-depleted mice. Anti-OX40
treatment had no effect on parasite control in the absence of
CD4 T cells (Figure 3A), supporting that CD4 T cells are functional
targets of agonistic a-OX40 mAb in vivo. Thus, we next exam-
ined whether a-OX40 treatment expanded one or more function-
ally distinct CD4 T cell subsets. We first focused on T-bet+ Th1
cells, as this subset is widely linked to protection against
blood-stage Plasmodium infection (Amante and Good, 1997;
De Souza et al., 1997; Langhorne et al., 1990; Oakley et al.,
2014). We found the fractions of effector CD4 T cells expressing
T-bet, the MFI of T-bet, and the total number of T-bet+ parasite-
specific CD4 T cells were significantly elevated in mice treated
with a-OX40 mAb (Figures 3B and 3C). The effects on T-bet
expression correlated with increases in the proportion of CD4
T cells competent to express IFN-g and interleukin (IL)-2 in
a-OX40-treated mice (Figures 3D and 3E). As a consequence
of the 3- to 4-fold expansion of parasite-specific effector CD4
T cells (Figure 2D), the total number of IFN-g expressing CD4
T cells was elevated approximately 5-fold in a-OX40-treatedost & Microbe 17, 628–641, May 13, 2015 ª2015 Elsevier Inc. 629
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Figure 1. OX40 Expression on CD4 T Cells during Clinical and Experimental Malaria
(A) Cumulative data displaying the MFI of OX40 (left) and PD-1 (right) expression on CD45RACD45RO+ (activated) CD4+ T cells in the peripheral blood of U.S.
controls (n = 15) and children in Mali (n = 26) at the healthy baseline (Before Malaria) and 7 days after diagnosis and treatment of acute P. falciparum malaria
(After Treatment). Data (mean ± SD) for P. falciparum-infected children were analyzed using paired Student’s t tests.
(B) Cumulative data depicting the association between the fold change in PD-1 MFI (Before Malaria to After Treatment) and parasite densities in the blood of
children at first diagnosis of acute malaria. Data were analyzed using linear regression.
(C–F) Mice were infected with 106 P. yoelii-infected RBCs, and splenocytes were isolated at the indicated time points.
(C) Representative plots showing the fraction of splenic P. yoelii-specific (CD11ahiCD49dhi) CD4 T cells and (CD11ahiCD8alo) CD8 T cells expressing OX40 on
day 7 p.i.
(D) Representative histograms (top) and summary kinetics (bottom, mean ± SD) of OX40 expression on splenic CD11ahiCD49dhi CD4 T cells from naive and
P. yoelii-infected mice on days 7, 14, 20, and 28 p.i. Dashed lines and shaded histograms represent naive T cells and isotype staining, respectively. Symbols
represent individual mice.
(E and F) Representative plots (E) and summary data (F) showing coordinate OX40 and PD-1 expression or LAG-3 and PD-1 expression among naive
(CD11aloCD49dlo) and activated (CD11ahiCD49dhi) splenic CD4 T cells on day 14 p.i. in chloroquine- versus saline-treated mice.
See also Figure S1.
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Parasite Control during Experimental
Malaria
(A) Experimental design. Mice were infected with
106 P. yoelii-infected RBCs and treated with con-
trol rat IgG, a-OX40L, or a-OX40 at the indicated
time points. Parasite burden (% Parasitemia) was
measured at regular intervals.
(B) Parasitemia on day 17 p.i. in mice administered
rat IgG (n = 8) or a-OX40L (n = 8). Symbols
represent individual mice. Data (mean ± SD) were
pooled from two independent experiments and
analyzed using Student’s t test.
(C) Parasite growth kinetics in mice (n = 5/group)
treated with rat IgG or a-OX40 on days 7 and 10 p.i.
(arrows). *p < 0.05, **p < 0.01. Data (mean ± SEM)
were analyzed using multiple t tests correcting
for multiple comparisons using the Holm-Sidak
method and are representative of 8 independent
experiments.
(D–F) Representative plots (D) and cumulative data
showing the frequency (E) and total numbers (F)
of CD11ahiCD49dhi CD4+ T cells on day 14 p.i. in
mice receiving rat IgG or a-OX40 on days 7 and
10 p.i. Data (mean ± SEM) in (E) and (F) are from
5–6 mice per group per time point and were
analyzed using multiple unpaired Student’s t tests
and are representative of 3 independent experi-
ments (***p < 0.0001, **p < 0.01, *p < 0.05).
See also Figure S2.P. yoelii-infected mice (Figure 3F). Unexpectedly, we also
observed protective effects of agonistic a-OX40 mAb when
it was administered to P. yoelii-infected IFN-g knockout
(GKO) mice on days 7 and 10 p.i. (Figure 3G). Enhanced parasite
control in GKO mice treated with a-OX40 was associated
with larger effector CD4 T cell responses (Figure S3A). Notably,
despite numerically equivalent GCB cell responses (Figure S3B),
a-OX40-treated GKO mice exhibited significantly larger
T-dependent, parasite-specific antibody responses compared
to rIgG-treated GKO mice (Figure S3C). Collectively, these
data show that therapeutic OX40 stimulation following P. yoelii
malaria expands the number of IFN-g-expressing Th1 CD4
T cells that may contribute to, but are not essential for, the
protective effects of agonistic a-OX40 mAb treatment.
Anti-OX40 Agonist Treatment Is Associated
with Expansion of Multiple CD4 T Cell Subsets and
Enhanced Parasite-Specific Antibody Responses
Because OX40 signaling is reported to promote the differentia-
tion and accumulation of CXCR5+CD4+ T cells (Walker et al.,
2000; Walker et al., 1999), we next examined features of
splenic parasite-specific Tfh cells in control- and a-OX40-
treated mice. Despite modest reductions in the proportion ofCell Host & Microbe 17, 628–Bcl-6+ effector CD4 T cells and the MFI
of Bcl-6 on day 14 p.i. (Figures 4A and
4B), the total number of Bcl-6+ CD4
T cells was, on average, 2-fold higher
in mice treated with a-OX40 agonistic
mAb (Figure 4C). When we examined Tfh
cells using canonical cell surface markers(CXCR5, PD-1, and ICOS), we found 3-fold larger Tfh responses
following a-OX40 agonist treatment (Figures S4A–S4C). Notably,
sort-purified CD4 effector T cells from control- and a-OX40-
treated P. yoelii-infected mice exhibited equivalent expression
of Bcl6 and Il21 mRNA (not shown). We also found significant
increases in the fraction and total number of GATA-3+ effector
CD4 T cells in a-OX40-treated mice (Figures S4D and S4E),
which correlated with elevated levels of serum IL-4 through
day 23 p.i. (Figure S4F). Finally, consistent with OX40 expression
on Tregs, we also observed a 35% expansion in the total number
of Foxp3+ Treg cells following a-OX40 agonist treatment (Figures
S4G and S4H). Collectively, these data demonstrate that
therapeutic OX40 stimulation expands and maintains not only
parasite-specific Th1 cells in P. yoelii-infected mice, but also
other functionally distinct CD4 T cell subsets, including Tfh cells.
Although Tfh cell numbers were expanded after a-OX40
treatment, compared to rIgG treatment, the total numbers of
splenic GC B cells were not statistically different between days
14 and 28 p.i. (Figures 4D and 4E). However, a-OX40-treated
mice harbored significantly higher numbers of splenic CD138+
IgDlo/ plasmablasts on day 14 p.i. (Figures 4F and 4G), a larger
fraction of which retained IgM expression (Figure S4I). Further
analyses suggested these non-switched plasmablasts derived641, May 13, 2015 ª2015 Elsevier Inc. 631
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Figure 3. Agonistic a-OX40 Enhances P. yoelii-Specific T Helper Type I Responses
(A–G) Mice were infected with 106 P. yoelii-infected RBCs and treated with rat IgG or a-OX40 on days 7 and 10 p.i.
(A) Parasitemia on day 9 p.i. in control (IgG) or CD4 T cell-depleted (a-CD4) mice. Data (mean ± SD) were analyzed using ANOVA. n = 10 mice per group pooled
from 2 independent experiments.
(B) Representative plots depicting T-bet expression in CD11ahiCD44hi CD4+ T cells on day 14 p.i.
(C) Cumulative data showing the MFI (left) and total number (right) of T-bet+CD11ahiCD44hi CD4+ T cells. Data (mean ± SD) were pooled from 3 independent
experiments and analyzed using unpaired Student’s t tests.
(D) Representative plots showing IFN-g and IL-2 expression on day 14 p.i. in CD11ahiCD49dhi CD4 T cells after ex vivo stimulation with PMA and ionomycin.
(E and F) Cumulative data showing the percent (E) and number (F) of IFN-g+ CD11ahiCD49dhiCD4+ T cells in rIgG (n = 13) and a-OX40-treated mice (n = 13).
Data (mean ± SD) were pooled from 3 independent experiments and analyzed using unpaired Student’s t tests.
(G) Parasitemia in IFN-g knockout (GKO) mice treated with either rIgG (n = 11) or a-OX40 (n = 11) on days 7 and 10 p.i. Data (mean ± SEM) are pooled
from3 independentexperimentsandwereanalyzedusingmultiple unpairedStudent’s t testswhilecorrecting formultiplecomparisonsusing theHolm-Sidakmethod.
Symbols in (C), (E), and (F) represent individual mice. See also Figure S3.from extra-follicular responses, as the vast majority (>85%) of
CD138+IgDlo/ cells were also GL-7lo/ (Figure S4J). Consistent
with numerically expanded populations of IgM+ plasmablasts
and elevated serum IL-4, a-OX40-treated mice displayed signifi-
cantly elevated merozoite surface protein 1 (MSP119)-specific
IgM (Figure 4H) and IgG1 (Figure 4I) titers, respectively. As a com-632 Cell Host & Microbe 17, 628–641, May 13, 2015 ª2015 Elsevier Iposite, these data show that, despite expanded Treg populations,
enhanced parasite control following therapeutic OX40 stimulation
during P. yoelii malaria is associated with enhanced extra-follic-
ular plasmablast formation, secretion of parasite-specific IgM,
sustained Tfh responses and GC reactions, and T-dependent
parasite-specific antibody class-switching to IgG1.nc.
SimultaneousBlockade of PD-1 andStimulation of OX40
during P. yoelii Malaria Results in Dysregulated
T Follicular Helper and Germinal Center B Cell
Reactions and Loss of Parasite Control
Given that exogenous a-OX40 stimulation can quantitatively
enhance parasite-specific CD4 T cell and antibody responses
and promote parasite control, and OX40 and PD-1 are coordi-
nately expressed on P. yoelli-specific CD4 T cells (Figure 1E),
we reasoned that simultaneously blocking the PD-1 co-inhibitory
pathway and stimulating the OX40 co-stimulatory pathway
would synergistically enhance CD4 T cell immunity and promote
resolution of blood-stage P. yoelii infection. To directly test this,
we co-administered a-PD-L1 blocking and a-OX40 agonistic
mAbs to P. yoelii-infected mice on days 7 and 10 p.i. PD-L1 is
a major ligand for the PD-1 co-inhibitory receptor, and mAbs
targeting PD-L1 have been used extensively to reverse PD-1-
mediated T cell exhaustion (Barber et al., 2006; Blackburn
et al., 2009; Butler et al., 2012). As predicted, combined PD-L1
blockade and OX40 stimulation (a-PD-L1 + a-OX40) markedly
suppressed parasite replication from days 8 to 11 p.i., even
more potently than a-OX40 alone (Figure 5A, inset). For clarity,
a-PD-L1 alone was omitted from the graph, but consistent with
our previous observations (Butler et al., 2012), this treatment
modestly restricted parasite growth (Figure S5A). Despite the
early enhanced control of parasite growth in a-PD-L1 +
a-OX40-treated mice, parasite burdens subsequently spiked
and mice succumbed to hyper-parasitemia by day 24 p.i. (Fig-
ure 5A). Importantly, both early suppression and eventual loss
of parasite control were also observed when using an a-PD-1
blocking mAb (Figure S5B), supporting that the effects of
a-PD-L1 were not due to disruption of interactions between
PD-L1 and a second documented PD-L1 binding partner,
CD80 (Butte et al., 2007). Notably, the relative degree of parasite
control in a-OX40- versus a-PD-L1 + a-OX40-treated mice was
not associated with marked changes in total RBC counts (Fig-
ure S5C). However, on average, weight loss, anemia, and liver
damage were most impacted in mice treated with both a-PD-
L1 and a-OX40 (Figures S5D–S5G), consistent with a modest
exacerbation of immunopathology.
Despite the subtle immunopathologic changes, the eventual
loss of parasite control following a-PD-L1 + a-OX40 treatment
was unexpected and suggests that functional crosstalk between
pathways of OX40 co-stimulatory and PD-1 co-inhibitory
signaling may modulate the differentiation and/or survival of
one or more CD4 T cell subsets required for Plasmodium resis-
tance. Thus, we next examined whether Tfh cells were affected
by the coordinate blockade of PD-1 and stimulation of OX40
signaling during P. yoelii malaria. Although the frequency and
total number of CD4 T cells exhibiting a CXCR5+PD-1+ Tfh cell
surface phenotype on day 14 p.i. were significantly elevated in
both a-OX40- and a-PD-L1 + a-OX40-treatedmice (Figure S5H),
the number of Bcl-6+ effector CD4 T cells was reduced by >65%
in mice treated with a-PD-L1 + a-OX40 (Figures 5B and 5C), with
Bcl-6 expression in CD4 T cells approaching undetectable
levels by day 20 p.i. (Figure 5B, right). Consistent with the
aborted Bcl-6+ Tfh response, we also found that parasite-
specific, T-dependent serum antibody responses (Figure S5I)
and the frequency of GL-7+ GCB cells (Figure 5D) weremarkedly
diminished by day 20 p.i. in a-PD-L1 + a-OX40-treated mice.Cell HNotably, of the GC B cells that could be detected on day 20
p.i. in a-PD-L1 + a-OX40-treated mice, fewer than 25% ex-
pressed the memory marker Bcl-6 (Figure 5D, right). Further-
more, by day 20 p.i. the total number of Bcl-6+ GC B cells
was reduced by >95% in P. yoelii-infected mice treated with
a-PD-L1 + a-OX40 (Figure 5E). Collectively, these data suggest
that pathways of OX40 co-stimulatory receptor signaling
may be modified by PD-1 co-inhibitory signaling in CD4 T cells
during rodent malaria, which markedly alters the differentiation
or maintenance of parasite-specific Tfh cells.
Serum IFN-g Levels Negatively Correlate with Germinal
Center BCell Numbers and Are Associatedwith Relative
Amounts of T-Bet and Bcl-6 in CD4 Effector T Cells
Exogenous OX40 stimulation in models of acute bacterial or
chronic viral infection abrogates Bcl-6-dependent Tfh cell
differentiation (Boettler et al., 2013; Marriott et al., 2014); Tfh
loss was linked to enhanced STAT5-dependent, IL-2/CD25
signaling and subsequent expression of Blimp-1 (Boettler
et al., 2013), a transcriptional repressor of Bcl-6 (Johnston
et al., 2009). During malaria, a-PD-L1 + a-OX40 treatment,
but not a-OX40 alone, also profoundly diminished Tfh re-
sponses. Thus, we examined these circuits in our control and
experimental P. yoelii-infected mice. Notably, we found no
increases in CD25 expression on effector CD4 T cells in
a-PD-L1 + a-OX40-treated mice (Figures S6A–S6C) and no
relationship between the levels of circulating IL-2 and the
magnitude of the GC B cell response in any group (Figures
S6D and S6E). Remarkably, of all the factors we examined,
only IFN-g correlated with loss of GC B cell activity (Figures
6A and 6B), humoral immunity, and pathogen control. Indeed,
we observed 10-fold increases in the number of splenic IFN-
g+ (Figure 6C) and T-bet+ (Figure 6D) Th1 effector CD4 T cells
on day 14 p.i. in a-PD-L1 + a-OX40-treated mice, relative to
control mice treated with rIgG. IFN-g can act in a feed-forward
mechanism to promote T-bet expression in Th1 cells (Djuretic
et al., 2007; Schulz et al., 2009), and T-bet can directly asso-
ciate with Bcl-6, thereby limiting the activity of this transcrip-
tional repressor (Oestreich et al., 2012). Moreover, Blimp-1
expression is elevated and Tfh gene expression profiles are
repressed in CD4 T cells ectopically expressing T-bet in vitro
(Oestreich et al., 2012; Oestreich and Weinmann, 2012). Thus,
we examined in vivo the relative ratios of T-bet versus Bcl-6
expression in effector CD4 T cells in our experiments. Strikingly,
ratios of T-bet/Bcl-6 expression in CD4 T cells (Figure 6E) and
T-bet/Bcl-6 MFI (Figure 6F) were markedly elevated in mice
administered both a-PD-L1 and a-OX40, which also positively
correlated with elevated Blimp-1 expression (Figures S6F–
S6H) and levels of serum IFN-g (Figure 6G). These data suggest
that a-PD-L1 + a-OX40 treatment induces excessive IFN-g pro-
duction, which may skew T-bet/Bcl-6 ratios in effector CD4
T cells and limit the development of Tfh and GC B cell re-
sponses and humoral immunity during Plasmodium infection.
Excessive IFN-g Is Necessary and Sufficient to
Dysregulate T Follicular Helper Cell and Germinal
Center B Cell Responses during P. yoelii Malaria
To formally examine a feed-forward role for IFN-g in limiting Tfh
activity and GC B cell reactions, we repeated our experiments inost & Microbe 17, 628–641, May 13, 2015 ª2015 Elsevier Inc. 633
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Figure 4. Agonistic a-OX40 Promotes Humoral Immunity during Experimental Malaria
(A–I) Mice were infected with 106 P. yoelii-infected RBCs and treated with rat IgG or a-OX40 on days 7 and 10 p.i.
(A) Representative plots showing Bcl-6 expression among splenic effector CD4+ T cells on day 14 p.i.
(B and C) Cumulative data (mean ± SD) showing the MFI of Bcl-6 expression and total number of Bcl-6+ parasite-specific CD4 T cells in rat IgG and a-OX40-
treated mice on day 14 p.i.
(D and E) Representative plots (D) and cumulative data (E) showing the kinetics of CD95+GL-7+CD19+ B cell responses in rat IgG and a-OX40-treated mice.
(F) Flow cytometric plots (left) and cumulative data (right) depicting the fraction of CD138hiIgDloCD19+B220+ plasmablasts on day 14 p.i.
(legend continued on next page)
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P. yoelii-infected GKO mice. As we observed for a-OX40 alone
(Figure 3G), the transient protective effects of a-PD-L1 +
a-OX40 were independent of IFN-g expression (Figure 7A).
Although mice lacking IFN-g eventually succumb to chronic par-
asitemia (data not shown), we identified that Bcl-6+ Tfh cell pop-
ulations (data not shown) and GC B cell responses (Figures 7B
and 7C) were numerically identical in rIgG- and a-PD-L1 +
a-OX40-treated GKO mice. Strikingly, despite equivalent cell
numbers, both the quantity and quality of T-dependent secreted
antibody were enhanced in GKO mice after administration of
both a-PD-L1 and a-OX40 mAbs (Figure S7A). Consistent with
our studies in GKO mice, neutralization of IFN-g in P. yoelii-in-
fected WT mice treated with a-PD-L1 + a-OX40 prolonged sur-
vival (not shown) and was associated with reduced parasitemia
on average (Figure S7B). To determine whether excess IFN-g
can be sufficient to impede T-dependent humoral immunity dur-
ing Plasmodium infection, we administered 1 mg of recombinant
IFN-g to P. yoelii-infected mice every 3 days from day 7 to 16 p.i.
Consistent with the apparent deleterious effect of IFN-g on para-
site control following a-PD-L1 + a-OX40 treatment, P. yoelii-in-
fected mice administered recombinant IFN-g also failed to fully
control parasite replication (Figure 7D). By day 20 p.i., mice
receiving exogenous IFN-g harbored 2-fold fewer Tfh and GC
B cells (Figures 7E and 7F), resulting in markedly reduced
T-dependent parasite-specific antibody titers (Figure S7C).
Importantly, we also observed dose-dependent effects of rIFN-
g on the number and frequency of Tfh cells (Figure 7G), GC B
cells (Figure S7D), and parasite burdens (Figure S7E). Collec-
tively, these data show that IFN-g can function as a negative
regulator of Tfh differentiation or maintenance, which impairs
parasite-specific antibody responses during malaria. Although
IFN-g is necessary for eventual resolution of blood-stage Plas-
modium infection, these data illustrate that in excess, IFN-g
sharply limits the survival or differentiation of Tfh cells that are
required to sustain GC B cell reactions and the secretion of pro-
tective anti-Plasmodium antibodies.
DISCUSSION
Here, we provide insight into how Plasmodium parasites impact
host immunity and identify that a specific host factor, OX40, can
be therapeutically targeted to enhance immune-mediated resis-
tance to Plasmodium infection. Moreover, our experiments
reveal a previously unknown mechanism of how biological
crosstalk between co-inhibitory and co-stimulatory pathways
can affect CD4 Tfh cell activity during experimental malaria.
OX40 is classically regarded as a transiently expressed co-
stimulatory receptor that regulates the proliferation and survival
of T cells via activation of NF-kB, Akt, survivins, and Bcl-2- and
Bcl-xL-dependent anti-apoptotic pathways (Song et al., 2005,
2007, 2008). Following acute infections, OX40 is downregulated
5–6 days after initial T cell activation (Croft, 2010). However, dur-(G) Kinetics of the plasmablast response (**p < 0.01).
(H and I) Cumulative data showing MSP119-specific IgM (H) and MSP119-specifi
23 p.i.
Cumulative data (mean ± SD) in (B)–(D) and (F) were pooled from 2 independent ex
(E) and (G) are from at least 5 mice per group per time point and were analyzed u
method. Data in (E) and (G)–(I) are representative of 3 independent experiments. S
Cell Hing chronic infections, such as with LCMV clone 13, OX40
expression is reportedly sustained for weeks (Boettler et al.,
2012, 2013; Salek-Ardakani et al., 2008). Our data show that
OX40 and PD-1 are upregulated on activated CD4 T cells during
human P. falciparum infection, with parasite burden closely
linked to PD-1 expression. We also show that OX40 is coordi-
nately expressed with PD-1 and LAG-3 co-inhibitory receptors
on parasite-specific CD4 T cells in rodents.
We tested the biological relevance of these observations by
therapeutically administering agonistic a-OX40 biologics to
P. yoelii-infected mice at the start of the second week of infec-
tion, which resulted in the substantial accumulation of multiple
subsets of parasite-specific effector CD4 T cells. Ligation of
OX40 also resulted in enhanced parasite control that correlated
with a profound expansion of CD138+IgD plasmablasts and
elevated serum titers of MSP119-specific IgM and IgG1. Notably,
the protective effects of a-OX40were also independent of IFN-g,
suggesting that parasite control was independent of Th1 effector
activity. Although our data show correlations between enhanced
humoral immunity following a-OX40 stimulation, additional CD4
T cell-intrinsic, IFN-g-independent pathways that potentially
contribute to protection warrant further investigation.
Notably, our results contrast sharply with the LCMV cl13
model, wherein exogenous a-OX40 administered on day 7 p.i.
had no effect on the phenotype, number, or function of virus-
specific CD4 T cells. Thus, compared to CD4 T cells responding
to persistent LCMV infection, Plasmodium-specific CD4 T cells
remain receptive to co-stimulatory signals well after their initial
activation. Regarding therapeutic strategies, a wider window to
manipulate effector CD4 T cell subset differentiation or activity
may therefore exist during malaria compared to chronic viral
infection.
Our data also reveal clear differences in the effects of a-OX40
ligation on Plasmodium-specific versus bacterial- or virus-spe-
cific CD4 T cells. For example, administration of a-OX40 mAb
1–2 days after either Listeria monocytogenes (Lm) or LCMV
infection prevented Tfh cell differentiation and abrogated humor-
al immunity (Boettler et al., 2013; Marriott et al., 2014), whereas
exogenous a-OX40 on days 7 and 10 post-P. yoelii infection
expanded parasite-specific Tfh cells. This discrepancy likely
reflects the time point at which the agonist was administered.
Most parasite-specific CD4 T cells may have already committed
to various pathways of differentiation after the first week
of P. yoelii infection. Thus, rather than skewing CD4 T cell differ-
entiation, a-OX40 administered on days 7 and 10 p.i. promoted
the expansion of multiple parasite-specific T helper subsets,
including Tfh cells, which in turn promoted T-dependent humoral
immunity. Consistent with our results, agonistic a-OX40 deliv-
ered to simian immunodeficiency virus (SIV)-infected macaques
also triggered marked increases in pathogen-specific antibody
titers. Furthermore, in a phase 1 clinical trial, patients receiving
a-OX40 mAb as an experimental therapy for metastatic solidc IgG1 (I) endpoint titers for rat IgG and a-OX40-treated mice on days 14 and
periments and analyzed using unpaired Student’s t tests. Data (mean ± SEM) in
sing multiple t tests, correcting for multiple comparisons using the Holm-Sidak
ymbols in (B)–(D), (F), (H), and (I) represent individual mice. See also Figure S4.
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Figure 5. Coordinate a-OX40 Ligation and PD-1 Blockade during Experimental Malaria Abrogates T Follicular Helper and Germinal Center
B Cell Responses
(A–E) Mice were infected with 106 P. yoelii-infected RBCs and treated with rat IgG, a-PD-L1, a-OX40, or a-PD-L1 and a-OX40 on days 7 and 10 p.i.
(A) Parasitemia kinetics (n = 5 mice/group). Data (mean ± SEM) are representative of 5 independent experiments.
(B) Representative dot plots showing PD1+CXCR5+ Tfh cells and histograms showing Bcl-6 expression on days 14 (left) and 20 (right) p.i.
(C) Cumulative data (mean ± SD) showing the total number of Bcl-6+ effector CD4 T cells on day 20 p.i. pooled from 2 independent experiments.
(D) Representative dot plots showing CD19+GL-7+ B cells and histograms showing Bcl-6 expression on days 14 (left) and 20 (right) p.i.
(E) Cumulative data (mean ± SD) showing the total number of Bcl-6+CD19+GL-7+ B cells on day 20 p.i. pooled from 3 independent experiments. Data in (C) and (E)
were analyzed using one-way ANOVA while correcting for multiple comparisons via the Tukey method.
Data in (B)–(E) are representative of 3 independent experiments. Symbols in (C) and (E) represent individual mice. See also Figure S5.
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Figure 6. Circulating Interferon-Gamma Levels Negatively Correlate with T-Dependent Humoral Immunity during Experimental Malaria
Mice were infected with 106 P. yoelii-infected RBCs and treated with rat IgG, a-PD-L1, a-OX40, or a-PD-L1 and a-OX40.
(A and B) Negative correlations between serum IFN-g and the frequency (A) and total number (B) of GC B cells. Data are pooled from 3 independent experiments
spanning days 14 to 20 p.i. and were analyzed using linear regression.
(C and D) Number of IFN-g+ (C) and T-bet+ (D) effector CD11ahiCD49dhi CD4 T cells on day 14 p.i.
(E and F) Ratios of T-bet+ versus Bcl-6+ (E) and MFI of T-bet versus Bcl-6 (F) in effector CD4 T cells on day 14 p.i.
(G) Positive correlation between circulating IFN-g and T-bet/Bcl-6 ratios in effector CD4 T cells on day 20 p.i. Data are pooled from 2 independent experiments.
Data (mean ± SD) in (C)–(F) were analyzed using one-way ANOVAswhile correcting formultiple comparisons via the Tukeymethod. All data are representative of 3
independent experiments. Symbols in (A)–(G) represent individual mice. See also Figure S6.malignancy exhibited significantly elevated antibody responses
against KLH and tetanus reporter antigens (Curti et al., 2013).
Multiple studies have reported impaired T-dependent humoral
immunity in OX40-deficient rodents (Boettler et al., 2012; Gaspal
et al., 2005), which is also consistent with the positive role of
OX40 signaling in regulating the induction of humoral immunity.Cell HCollectively, these data suggest that OX40 co-stimulation can
either promote or constrain humoral immunity depending on
whenOX40 signaling is triggered relative to initial T cell activation
and the nature of the infection or immunization. Therefore, stra-
tegies designed to modulate OX40 signaling warrant consider-
ation of these relationships.ost & Microbe 17, 628–641, May 13, 2015 ª2015 Elsevier Inc. 637
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Figure 7. Interferon-Gamma Constrains T Follicular Helper Responses and Humoral Immunity during Experimental Malaria
Mice were infected with 106 P. yoelii-infected RBCs and treated with rat IgG or a-PD-L1 and a-OX40 (A–C), or with PBS or rIFN-g (D–G) at the indicated time
(arrows).
(A) Parasitemia (mean ± SEM) in IFN-g knockout (GKO) mice treated with rat IgG (n = 5) or a-PD-L1 + a-OX40 (n = 5).
(B) Representative plots (left) and histograms (right) depicting the frequency of GC B cells expressing Bcl-6 on day 20 p.i. in P. yoelii-infected GKO mice treated
with rat IgG or a-PD-L1 and a-OX40.
(C) Number of GC B cells on day 20 p.i. Data (mean ± SD) were analyzed using an unpaired Student’s t test.
(D) Parasitemia kinetics (left) and parasitemia on day 19 p.i. (right) inP. yoelii-infectedmice treatedwith PBS or 1 mg rIFN-g. Data (mean ± SEM) are from 9mice per
group.
(E) Representative plots (left) and summary data (right) showing the fraction and total number of CXCR5+PD-1+ effector CD4 T cells on day 20 p.i. in mice treated
with PBS or 1 mg rIFN-g. Data (mean ± SD) were analyzed using unpaired Student’s t tests.
(legend continued on next page)
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The extent to which pathways of co-stimulation and co-inhibi-
tion integrate to shape T cell function is an area that has only
recently received attention, even though biologics targeting
both types of pathways are already in independent clinical trials
(Chen and Flies, 2013). Thus, we additionally explored whether
simultaneously blocking PD-1 and activating OX40 signaling
during P. yoelii malaria would synergistically enhance CD4
T cell activity and parasite control. Strikingly, combined adminis-
tration of biologics to manipulate these pathways resulted in
the complete loss of parasite-specific Tfh cell activity and GC
B cell reactions, which rendered mice profoundly susceptible
to Plasmodium. The a-OX40-induced block in LCMV-specific
Tfh development noted above was linked to enhanced IL-2
signaling and STAT5-mediated transactivation of Blimp-1
(Boettler et al., 2013). Although Blimp-1 was elevated in CD4
T cells in a-OX40 + a-PD-L1-treated mice, we found that
serum IFN-g levels, but not IL-2, most strongly correlated with
loss of GC B cells.
T-bet is required for Th1 activity and expression of IFN-g by
Th1 T cells (Szabo et al., 2000). Although T-bet activity is
commonly associated with IL-12 signaling, IFN-g signaling
through the IFN-g receptor (IFNGP)-STAT1 pathway also
induces T-bet expression (Afkarian et al., 2002). Thus, IFN-g
can further potentiate T-bet expression through a feed-forward
mechanism (Djuretic et al., 2007; Schulz et al., 2009). Notably,
T-bet can directly complex with Bcl-6 and thereby block Bcl-6-
mediated suppression of Blimp-1 (Oestreich et al., 2012;
Oestreich and Weinmann, 2012). As a consequence, when pre-
sent in excess, T-bet indirectly represses Tfh gene signatures.
Given this, we examined the relative ratios of T-bet versus
Bcl-6 expression in effector CD4 T cells in vivo. Mice treated
with both a-PD-L1 and a-OX40 exhibited the highest ratios of
T-bet to Bcl-6 MFI and also expressed the highest levels of
Blimp-1, indicative of reduced Bcl-6 activity. Remarkably, in
mice lacking IFN-g, a-PD-L1 + a-OX40 treatment triggered
sustained GC reactions, increased MSP119-specific antibody
titers, and enhanced parasite control. Furthermore, administra-
tion of rIFN-g was sufficient to decrease the frequencies and
total numbers of Tfh and GCB cells and reduce parasite-specific
antibody titers. Notably, excessive IFN-g is reported to drive
pathologically large Tfh responses that contribute to autoimmu-
nity (Lee et al., 2012). While the reasons for these discrepancies
are unclear, it is possible that IFN-gmay restrict the formation or
maintenance of Tfh during systemic infection compared to the
genetic model of lupus. Indeed, our data support that excessive
IFN-g (and excess T-bet) can be detrimental to T-dependent
humoral immunity during prolonged P. yoelii infection, which is
consistent with a clinical study of P. falciparum-infected patients
that showed that high concentrations of serum IFN-gwere asso-
ciated with low parasite-specific IgM and IgG titers (Fernandes
et al., 2008). Dissecting the relative contribution of these
pathways during human malaria, in which P. falciparum-specific(F) Total number of CD95+GL-7+ GC B cells on day 20 p.i. in mice treated with PB
tests.
(G) Dose-dependent effects of rIFN-g on themagnitude of the PD-1hiCXCR5+ CD4
ANOVA while correcting for multiple comparisons via the Tukey method.
Data (mean ± SEM) in (A) and (D) were analyzed using multiple t tests while correc
(A)–(G) are representative of 3 independent experiments. See also Figure S7.
Cell Hantibody responses are relatively short-lived, particularly in
children (Portugal et al., 2013), remains an important goal.
Collectively, our results reveal the profound impact that
crosstalk between PD-1 co-inhibitory and OX40 co-stimulatory
pathways has on immune modulation during experimental
malaria. Although a-OX40 treatment alone promoted T-bet
expression in effector CD4 T cells, numbers of Bcl-6+ Tfh cells
were expanded, and humoral immunity was also enhanced.
Strikingly, an uncoupling of PD-1 co-inhibitory signaling during
concurrent exogenous OX40 stimulation led to a significant in-
crease in T-bet and a dramatic reduction in Bcl-6 expression
and activity in parasite-specific CD4 T cells. These data demon-
strate that PD-1 signaling can function as a potent negative
regulator of Th1 effector differentiation, which in turn facilitates
the generation of a more effective Tfh response. Furthermore,
we provide evidence that co-stimulatory pathways may directly
counterbalance co-inhibitory pathways, as exogenous OX40
stimulation markedly enhanced numerical and functional attri-
butes of P. yoelii-specific CD4 T cells. A greater dissection of
the crosstalk and counterbalance between co-stimulatory and
co-inhibitory pathways will inform future immunotherapeutic
strategies focused on eliciting distinct pathways of CD4 T cell
differentiation during infection or cancer.
EXPERIMENTAL PROCEDURES
Ethical Approval
The Ethics Committee of the Faculty of Medicine, Pharmacy and Dentistry at
the University of Sciences, Technique and Technology of Bamako and the
IRB of the NIAID, NIH approved the human components of this study. Written
informed consent was obtained from adult participants and from the parents or
guardians of participating children.
Mali Study Site and Design
The field study was conducted in the rural village of Kalifabougou, Mali,
where intense P. falciparum transmission occurs from June through
December each year. The cohort study has been described in detail previ-
ously (Tran et al., 2013). Briefly, 695 healthy children and adults aged 3months
to 25 years were enrolled in an ongoing cohort study in May 2011. Exclusion
criteria at enrollment included a hemoglobin level < 7 g/dl, axillary tempera-
ture R 37.5C, acute systemic illness, underlying chronic disease, or use of
antimalarial or immunosuppressive medications in the past 30 days. For this
study, we identified 26 children aged 6–12 years who were asymptomatic
and not infected with P. falciparum (by PCR) in May 2013, and who also
had peripheral blood mononuclear cells (PBMCs) available at the end of the
6-month dry season (May 2013) and 7 days after treatment of their first febrile
malaria episode of the ensuing 6-month malaria season. Clinical malaria was
defined as R2,500 asexual parasites/ml, an axillary temperature R 37.5C,
and no other cause of fever discernible by physical exam. Malaria episodes
were detected prospectively by self-referral to the study clinic and through
weekly active clinical surveillance. All individuals with signs and symptoms
of malaria and any level of parasitemia detected by light microscopy were
treated according to the Malian National Malaria Control Program guidelines.
PBMCs from healthy adult donors (n = 15) and a blood bank in the U.S. were
analyzed. Demographic and travel history data were not available from these
anonymous donors, but prior P. falciparum exposure was unlikely. BloodS or 1 mg rIFN-g. Data (mean ± SD) were analyzed using unpaired Student’s t
T cell responses on day 20 p.i. Data (mean ± SD) were analyzed using one-way
ting for multiple comparisons using the Holm-Sidak method (*p < 0.05). Data in
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samples were obtained for research use after written informed consent was
obtained from all study participants enrolled in a protocol approved by the
IRB noted above (protocol 99-CC-0168).
Human and Mouse T Cells
For human studies, at each of the aforementioned time points, blood
samples were obtained by venipuncture into sodium citrate-containing tubes
(Vacutainer CPT Tubes; BD), and PBMCs were isolated according to the
manufacturer’s instructions and frozen in FBS containing 7.5% (v/v) DMSO
(Sigma-Aldrich), kept at 80C for 24 hr, and then stored at 196C in liquid
nitrogen until use. Human and mouse cells were analyzed with flow cytometry
as detailed in the Supplemental Experimental Procedures.
Mice, Parasites, and Biologics
C57BL/6 mice (8 weeks, 18–22 g) were purchased from Jackson Laboratories
and housed in the Biomedical Sciences Building at OUHSC. The OUHSC
IACUC approved all experiments. Plasmodium yoelii (clone 17XNL, obtained
from MR4, ATCC) was routinely passaged through mosquitoes, and mouse
infectionswere initiated by serial transfer of 106 parasite-infected red blood cells
via tail vein injection. Parasitemia was measured using flow cytometry as
described (Malleret et al., 2011). Giemsa staining of thin blood smears was
done in parallel. At the indicated times, mice were injected i.p. with 200 mg
a-CD4 (GK1.5), 500 mg of a-IFN-g (XMG1.2), 200 mg a-PD-L1 (10F.9G2), 50 mg
of a-OX40 Ab (OX86), 200 mg a-PD-L1 and 50 mg a-OX40, or 200 mg a-PD-1
(RMP1-14) and 50 mg a-OX40, or equivalent amounts of rat IgG. All biologics
were acquired from BioXcell. Recombinant IFN-g was acquired from Tonbo.
Statistical Analyses
Statistical analyses were performed using GraphPad Prism 6 software
(GraphPad). Specific tests of statistical significance are detailed in the figure
legends.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.chom.2015.03.007.
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